ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today
Frontdoor (NASDAQ:FTDR) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.45 by 24.44 percent. This is a 38.46 percent decrease over earnings of $0.91 per share from the same